Joseph L. Witztum

92.9k total citations · 36 hit papers
460 papers, 72.1k citations indexed

About

Joseph L. Witztum is a scholar working on Immunology, Surgery and Biochemistry. According to data from OpenAlex, Joseph L. Witztum has authored 460 papers receiving a total of 72.1k indexed citations (citations by other indexed papers that have themselves been cited), including 219 papers in Immunology, 181 papers in Surgery and 123 papers in Biochemistry. Recurrent topics in Joseph L. Witztum's work include Atherosclerosis and Cardiovascular Diseases (197 papers), Antioxidant Activity and Oxidative Stress (123 papers) and Lipoproteins and Cardiovascular Health (117 papers). Joseph L. Witztum is often cited by papers focused on Atherosclerosis and Cardiovascular Diseases (197 papers), Antioxidant Activity and Oxidative Stress (123 papers) and Lipoproteins and Cardiovascular Health (117 papers). Joseph L. Witztum collaborates with scholars based in United States, Canada and Austria. Joseph L. Witztum's co-authors include Daniel Steinberg, Wulf Palinski, Sotirios Tsimikas, Christopher K. Glass, Daniel Steinberg, T E Carew, John C. Khoo, Elizabeth R. Miller, Christoph J. Binder and Franklin H. Epstein and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Joseph L. Witztum

454 papers receiving 70.1k citations

Hit Papers

Beyond Cholesterol 1984 2026 1998 2012 1989 2001 1991 1989 1984 1000 2.0k 3.0k 4.0k 5.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Beyond Cholesterol
    1989 5.5k citations Franklin H. Epstein, Daniel Steinberg et al. New England Journal of Medicine profile →
  2. Atherosclerosis
    2001 2.5k citations Christopher K. Glass, Joseph L. Witztum profile →
  3. Role of oxidized low density lipoprotein in atherogenesis.
    1991 2.3k citations Joseph L. Witztum, Daniel Steinberg Journal of Clinical Investigation profile →
  4. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.
    1989 1.6k citations Wulf Palinski, T E Carew et al. Journal of Clinical Investigation profile →
  5. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids.
    1984 1.4k citations Joseph L. Witztum, Daniel Steinberg et al. profile →
  6. A comprehensive classification system for lipids
    2005 1.3k citations Christopher K. Glass, Joseph L. Witztum et al. Journal of Lipid Research profile →
  7. The oxidation hypothesis of atherosclerosis
    1994 1.1k citations Joseph L. Witztum profile →
  8. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions.
    1991 771 citations Joseph L. Witztum, Daniel Steinberg et al. profile →
  9. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase
    1999 749 citations Christoph J. Binder, Joseph L. Witztum et al. profile →
  10. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions.
    1997 714 citations Joseph L. Witztum, Wulf Palinski et al. Journal of Clinical Investigation profile →
  11. Structural Identification by Mass Spectrometry of Oxidized Phospholipids in Minimally Oxidized Low Density Lipoprotein That Induce Monocyte/Endothelial Interactions and Evidence for Their Presence in Vivo
    1997 659 citations Andrew D. Watson, Norbert Leitinger et al. Journal of Biological Chemistry profile →
  12. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
    2020 641 citations Sotirios Tsimikas, Ewa Karwatowska‐Prokopczuk et al. New England Journal of Medicine profile →
  13. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
    1998 631 citations Joseph L. Witztum, Wulf Palinski et al. profile →
  14. RNA-Targeted Therapeutics
    2018 612 citations Joseph L. Witztum et al. profile →
  15. Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease
    2005 594 citations Sotirios Tsimikas, Elizabeth R. Miller et al. New England Journal of Medicine profile →
  16. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL
    2003 590 citations Christoph J. Binder, Sohvi Hörkkö et al. profile →
  17. Lipoprotein Management in Patients With Cardiometabolic Risk
    2008 545 citations Joseph L. Witztum et al. profile →
  18. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
    2016 544 citations Richard S. Geary, Shuting Xia et al. profile →
  19. Innate and acquired immunity in atherogenesis
    2002 541 citations Christoph J. Binder, Mi-Kyung Chang et al. profile →
  20. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein.
    1990 533 citations Wulf Palinski, Joseph L. Witztum et al. profile →
  21. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity
    2000 529 citations Peter X. Shaw, Sohvi Hörkkö et al. Journal of Clinical Investigation profile →
  22. Probucol inhibits oxidative modification of low density lipoprotein.
    1986 510 citations Joseph L. Witztum, Daniel Steinberg et al. Journal of Clinical Investigation profile →
  23. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
    2017 454 citations Bruce L. Tai, Eunju Hurh et al. New England Journal of Medicine profile →
  24. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans
    2016 454 citations Calvin Yeang, Amir Ravandi et al. Circulation profile →
  25. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
    2019 416 citations Joseph L. Witztum, Daniel Gaudet et al. New England Journal of Medicine profile →
  26. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
    2015 409 citations Daniel Gaudet, Veronica J. Alexander et al. New England Journal of Medicine profile →
  27. Targeting APOC3 in the Familial Chylomicronemia Syndrome
    2014 381 citations Daniel Gaudet, Veronica J. Alexander et al. New England Journal of Medicine profile →
  28. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
    2015 358 citations Sotirios Tsimikas, Steven G. Hughes et al. profile →
  29. Statin therapy increases lipoprotein(a) levels
    2019 336 citations Sotirios Tsimikas, Philip L.S.M. Gordts et al. European Heart Journal profile →
  30. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis
    2018 329 citations Sotirios Tsimikas, Joseph L. Witztum et al. profile →
  31. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
    2015 296 citations Romain Capoulade, Kwan L. Chan et al. profile →
  32. An AMPK–caspase-6 axis controls liver damage in nonalcoholic steatohepatitis
    2020 236 citations Peng Zhao, Xiaoli Sun et al. Science profile →
  33. Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis
    2019 208 citations Sotirios Tsimikas, Benoît J. Arsenault et al. profile →
  34. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk
    2021 146 citations Ewa Karwatowska‐Prokopczuk, Seth J. Baum et al. European Heart Journal profile →
  35. Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol
    2022 123 citations Calvin Yeang, Ewa Karwatowska‐Prokopczuk et al. profile →
  36. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
    2024 112 citations Ewa Karwatowska‐Prokopczuk, Thomas A Prohaska et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joseph L. Witztum United States 139 26.5k 21.8k 18.4k 14.9k 10.4k 460 72.1k
Daniel Steinberg United States 105 10.1k 0.4× 14.0k 0.6× 11.2k 0.6× 10.7k 0.7× 5.4k 0.5× 439 42.8k
David G. Harrison United States 134 10.0k 0.4× 7.3k 0.3× 14.1k 0.8× 3.2k 0.2× 20.4k 2.0× 400 60.5k
Göran K. Hansson Sweden 101 28.1k 1.1× 9.5k 0.4× 14.0k 0.8× 1.8k 0.1× 7.2k 0.7× 455 53.2k
Alan M. Fogelman United States 92 7.2k 0.3× 10.7k 0.5× 8.5k 0.5× 4.4k 0.3× 3.4k 0.3× 266 31.5k
Stanley L. Hazen United States 119 10.1k 0.4× 7.4k 0.3× 26.2k 1.4× 2.5k 0.2× 6.4k 0.6× 481 55.1k
Yūji Matsuzawa Japan 123 8.3k 0.3× 14.8k 0.7× 16.7k 0.9× 1.8k 0.1× 16.7k 1.6× 700 80.5k
Bart Staels France 147 7.8k 0.3× 17.1k 0.8× 41.5k 2.3× 1.3k 0.1× 6.0k 0.6× 789 78.9k
Alan R. Tall United States 119 7.8k 0.3× 24.6k 1.1× 16.9k 0.9× 1.2k 0.1× 5.2k 0.5× 365 45.3k
Antonio M. Gotto United States 88 4.8k 0.2× 26.6k 1.2× 9.9k 0.5× 1.5k 0.1× 11.7k 1.1× 605 50.0k
Jay W. Heinecke United States 99 8.9k 0.3× 5.7k 0.3× 8.4k 0.5× 4.5k 0.3× 2.3k 0.2× 266 29.3k

Countries citing papers authored by Joseph L. Witztum

Since Specialization
Citations

This map shows the geographic impact of Joseph L. Witztum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph L. Witztum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph L. Witztum more than expected).

Fields of papers citing papers by Joseph L. Witztum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph L. Witztum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph L. Witztum. The network helps show where Joseph L. Witztum may publish in the future.

Co-authorship network of co-authors of Joseph L. Witztum

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph L. Witztum. A scholar is included among the top collaborators of Joseph L. Witztum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph L. Witztum. Joseph L. Witztum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Prohaska, Thomas A, Veronica J. Alexander, Ewa Karwatowska‐Prokopczuk, et al.. (2023). APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia. Journal of clinical lipidology. 17(3). 406–411. 36 indexed citations
2.
Curtis, Brian R., Lijiang Shen, Eugene Schneider, et al.. (2020). Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia. Nucleic Acid Therapeutics. 30(2). 94–103. 26 indexed citations
3.
Zhao, Peng, Xiaoli Sun, Zhongji Liao, et al.. (2020). An AMPK–caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. Science. 367(6478). 652–660. 236 indexed citations breakdown →
4.
Gaudet, Daniel, Ewa Karwatowska‐Prokopczuk, Seth J. Baum, et al.. (2020). Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. European Heart Journal. 41(40). 3936–3945. 196 indexed citations
5.
Tsimikas, Sotirios, Philip L.S.M. Gordts, Chelsea Nora, Calvin Yeang, & Joseph L. Witztum. (2019). Statin therapy increases lipoprotein(a) levels. European Heart Journal. 41(24). 2275–2284. 336 indexed citations breakdown →
6.
Prohaska, Thomas A, Xuchu Que, Cody J. Diehl, et al.. (2018). Massively Parallel Sequencing of Peritoneal and Splenic B Cell Repertoires Highlights Unique Properties of B-1 Cell Antibodies. The Journal of Immunology. 200(5). 1702–1717. 37 indexed citations
7.
Capoulade, Romain, Kwan L. Chan, Patrick Mathieu, et al.. (2017). Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial. Atherosclerosis. 260. 1–7. 7 indexed citations
8.
Verbeek, Rutger, S. Matthijs Boekholdt, Robert M. Stoekenbroek, et al.. (2016). Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. Journal of Lipid Research. 57(4). 697–705. 28 indexed citations
9.
Lichtman, Andrew H., Christoph J. Binder, Sotirios Tsimikas, & Joseph L. Witztum. (2013). Adaptive immunity in atherogenesis: new insights and therapeutic approaches. Journal of Clinical Investigation. 123(1). 27–36. 157 indexed citations
10.
Amir, Shahzada, Karsten Hartvigsen, Ayelet Gonen, et al.. (2012). Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. Journal of Lipid Research. 53(7). 1316–1326. 43 indexed citations
11.
Ravandi, Amir, S. Matthijs Boekholdt, Ziad Mallat, et al.. (2011). Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. Journal of Lipid Research. 52(10). 1829–1836. 110 indexed citations
12.
Stoletov, Konstantin, Longhou Fang, Soo-Ho Choi, et al.. (2009). Vascular Lipid Accumulation, Lipoprotein Oxidation, and Macrophage Lipid Uptake in Hypercholesterolemic Zebrafish. Circulation Research. 104(8). 952–960. 212 indexed citations
13.
Cruz, Daniel, Andrew D. Watson, Christopher S. Miller, et al.. (2008). Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. Journal of Clinical Investigation. 118(8). 2917–2928. 130 indexed citations
14.
Hartvigsen, Karsten, Christoph J. Binder, Lotte F. Hansen, et al.. (2007). A Diet-Induced Hypercholesterolemic Murine Model to Study Atherogenesis Without Obesity and Metabolic Syndrome. Arteriosclerosis Thrombosis and Vascular Biology. 27(4). 878–885. 84 indexed citations
15.
Gotsman, Israel, Nir Grabie, Rajat M. Gupta, et al.. (2006). Impaired Regulatory T-Cell Response and Enhanced Atherosclerosis in the Absence of Inducible Costimulatory Molecule. Circulation. 114(19). 2047–2055. 182 indexed citations
16.
Miller, Yury I., Mi-Kyung Chang, Christoph J. Binder, Peter X. Shaw, & Joseph L. Witztum. (2003). Oxidized low density lipoprotein and innate immune receptors. Current Opinion in Lipidology. 14(5). 437–445. 139 indexed citations
17.
Silverman, Gregg J., Peter X. Shaw, Marvin G. Chang, et al.. (2000). Neo-self Antigens and the Expansion of B-1 Cells: Lessons from Atherosclerosis-prone Mice. Current topics in microbiology and immunology. 252. 189–200. 16 indexed citations
18.
Witztum, Joseph L.. (1998). Basic Requirements for Investigational New Drug and New Drug Application Approval for an Antioxidant Compound in Cardiovascular Disease. The American Journal of Cardiology. 81(8). 50F–51F. 1 indexed citations
19.
Watson, Andrew D., Norbert Leitinger, Mohamad Navab, et al.. (1997). Structural Identification by Mass Spectrometry of Oxidized Phospholipids in Minimally Oxidized Low Density Lipoprotein That Induce Monocyte/Endothelial Interactions and Evidence for Their Presence in Vivo. Journal of Biological Chemistry. 272(21). 13597–13607. 659 indexed citations breakdown →
20.
Epstein, Franklin H., et al.. (1989). Beyond Cholesterol. New England Journal of Medicine. 320(14). 915–924. 5505 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Steinberg Breakdown of academic impact, for papers by David G. Harrison Breakdown of academic impact, for papers by Göran K. Hansson Breakdown of academic impact, for papers by Alan M. Fogelman Breakdown of academic impact, for papers by Stanley L. Hazen Breakdown of academic impact, for papers by Yūji Matsuzawa Breakdown of academic impact, for papers by Bart Staels Breakdown of academic impact, for papers by Alan R. Tall Breakdown of academic impact, for papers by Antonio M. Gotto Breakdown of academic impact, for papers by Jay W. Heinecke
Rankless by CCL
2026